Anesiva Presents Data On Pain Drug, 4975, Demonstrating Pain Reduction For Up To Two Weeks After Knee Replacement Surgeries

... Anesiva, Inc. (Nasdaq: ANSV) presented positive, clinical data from a Phase 2 clinical trial in total knee replacement surgeries with drug candidate, 4975, the company's novel, long-acting, non-opioid drug candidate being developed for site-specific, moderate-to-severe pain. [click link for full article] ...